Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories

Petco Health and Wellness

Pets are a big part of the family in America and that trend is only growing. Here are some top pet stocks to help you profit from the trend.

The 3 Best Pet Stocks to Buy Now

Mastercard

These stocks are relatively cheap and have a boatload of potential.

Got $5,000? Here Are 2 Top Growth Stocks to Buy for July

GREENFIELD, Ind.--(BUSINESS WIRE)--Each long-awaited summer brings a new, upbeat anthem for blaring with the car windows down or tapping your paws on the trail. This summer's anthem is for the dogs and cats. Released today by some of the most popular pets on Instagram including @KellyBove, @LouboutinaNYC, @TheHuskyMoon, @SuperCorgi_Jojo and @White_Coffee_Cat, "Unleash Joy" is now available to use on Instagram Reels. Pet-lovers can also enjoy the jubilant music video at https://youtu.be/JZUbAIty

New Anthem from Seresto Could be the 2022 Song of the Summer

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference, June 13-14, 2022. Todd Young, executive vice president and CFO, will participate in a fireside chat on Monday, June 13 at 6:20 p.m. ET (3:20 p.m. PT). A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal He

Elanco to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on Wednesday, June 1, 2022. Jeff Simmons, president and CEO, will participate in a fireside chat at 3:00 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health (NYSE: ELAN) is a global leader in animal health de

Elanco to Participate in Stifel 2022 Jaws and Paws Conference

Anthem

Bristol-Myers

Zoetis

The Vanguard Health Care Fund (Trades, Portfolio) recently disclosed its first quarter 2022 portfolio, revealing that its top five trades for the quarter included a new position in Zoetis Inc. ( ZTS , Financial), a boost to its holding in Daiichi Sankyo Co. Ltd. ( TSE:4568 , Financial), the closure of its position in Elanco Animal Health Inc. ( ELAN , Financial) and reductions to its holdings in Bristol-Myers Squibb Co. ( BMY , Financial) and Anthem Inc. ( ANTM , Financial).

Vanguard Health Care Fund's Top 5 Trades in the 1st Quarter

Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Katy Grissom - Head of IR Jeffrey Simmons - CEO Todd Young - CFO Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - BofA Securities Merrill Lynch Nathan Rich - Goldman Sachs Chris Scott - JPMorgan Umer Raffat - Evercore ISI Michael Parolari - Raymond James Jonathan Block - Stifel Balaji Prasad - Barclays Steve Scala - Cowen Christine Raines - William Blair Operator Good morning. My name is Rob, and I will be your conference operator today.

Elanco Animal Health Incorporated (ELAN) CEO Jeffrey Simmons on Q1 2022 Results - Earnings Call Transcript

Elanco Animal Health Inc (NYSE: ELAN) has reported a Q1 EPS of $0.36, lower than the $0.37 reported a year ago, surpassing analysts' view of $0.35. Revenue was $1.225 billion, a decrease of 1% YY, slightly above the consensus of $1.22 billion.

Elanco Animal Health Cuts FY22 Guidance After Q1 Earnings Beat Expectations Marginally

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 2.86% and 0.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Surpasses Q1 Earnings and Revenue Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2022, provided guidance for the second quarter of 2022, and updated guidance for the full year 2022. “Our first quarter financial results demonstrate continued consistent delivery and strong execution across our global enterprise with revenue, adjusted EBITDA and adjusted EPS all exceeding the mid-point of our guidance. We are already seeing the benefits of

Elanco Animal Health Reports First Quarter 2022 Results

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Elanco (ELAN) This Earnings Season?

DocGo

Singular Genomics Systems

Improved patient volumes, a diversified healthcare portfolio and various technological advancements are likely to favor first-quarter results of ELAN, DCGO and OMIC.

3 Healthcare Stocks Poised to Surpass Earnings Estimates in Q1

GREENFIELD, Ind. & HEERLEN, Netherlands--(BUSINESS WIRE)--Elanco Animal Health Incorporated (ELAN: NYSE) and Royal DSM have created a strategic alliance connecting two leading, sustainability-focused companies to address one of society's most significant opportunities of the decade, mitigating climate change by reducing greenhouse gas emissions from farming. Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer® for beef and dairy cattle. Bovaer

Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® – A Revolutionary, Methane-Reducing Feed Product for Cattle

Elanco Animal Health is coming off a record 2021 highlighted by strong earnings. The stock has been under pressure amid macro concerns including an ongoing Bird Flu outbreak with an uncertain impact on the company's poultry business.

Elanco Animal Health: Bullish Beyond Near-Term 'Bird Flu' Headwinds

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2022 financial results on Monday, May 9, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's w

Elanco Confirms Date and Conference Call for First Quarter 2022 Financial Results Announcement

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today unveiled plans for its new global headquarters featuring environmentally-sustainable, employee-focused design and a state-of-the art innovation center. The company – which grew from a small division of Eli Lilly & Company to a $4.7 billion independent global animal health leader – plans to enter its seventh decade by breathing life into a long-idle site close to its birthplace. “When we talk about the ne

Elanco Breaks Ground on State-of-the-Art Campus, Creating Indianapolis' Newest Landmark

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced that as of 5:00 p.m., New York City time, on April 11, 2022 (the “Early Tender Time”), holders of approximately $406,391,000 aggregate principal amount, or approximately 54.19% of the outstanding principal amount, of its outstanding 4.272% Senior Notes due 2023 (the “Notes”) had tendered their Notes pursuant to Elanco's previously announced tender offer (the “Offer”). Elanco also announc

Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes

Ginkgo Bioworks Holdings

Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and.

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm

BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring GREENFIELD, Ind. and BOSTON , April 11, 2022 /PRNewswire/ --  Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and  Ginkgo Bioworks , the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.

Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced the commencement of a cash tender offer (the “Offer”) for up to $250 million aggregate principal amount of its 4.272% Senior Notes due 2023 (CUSIP No. 28414HAE3) (the “Notes”), upon the terms and conditions set forth in the Offer to Purchase dated March 29, 2022. The Offer is scheduled to expire at 12:00 midnight, New York City time, at the end of April 25, 2022 (unless extended) (the “E

Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes

Elanco's world-wide animal health business is growing and recession-resistant.

Elanco's Tangible Equity Units: Low Risk With A 6% Yield

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (ELAN: NYSE) today announces the expansion of its shared value footprint across Sub-Saharan Africa, delivering on its 2030 pledge to create sustainable development solutions for those who depend on livestock for their livelihoods. MAHABA (Managing Animal Health and Acaricides for a Better Africa) is Elanco's second shared value initiative and aims to support small-scale producers in Nigeria and Uganda by defining and implement

Elanco Expands Commitment to Creating Shared Value, Launches New Initiative Empowering Small-Scale Producers in Sub-Saharan Africa

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q4 2021 Results - Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 23.53% and 1.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Q4 Earnings and Revenues Beat Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2021, and provided initial guidance both for the first quarter and full year 2022. “2021 was a historic year for Elanco as we completed our independent company standup, continued our integration of Bayer Animal Health and recorded our highest revenue and adjusted EBITDA levels as a public company. We grew revenue 7 percent compared to our 20

News for Elanco Animal Health Inc Stock (ELAN)